Understanding the dynamics of human liver metabolism is fundamental for effective diagnosis and treatment of liver diseases. This knowledge can be obtained with systems biology/medicine approaches that account for the complexity of hepatic responses and their systemic consequences in other organs. Computational modeling can reveal hidden principles of the system by classification of individual components, analyzing their interactions and simulating the effects that are difficult to investigate experimentally. Herein, we review the state-of-the-art computational models that describe liver dynamics from metabolic, gene regulatory, and signal transduction perspectives. We focus especially on large-scale liver models described either by genome scale metabolic networks or an object-oriented approach. We also discuss the benefits and limitations of each modeling approach and their value for clinical applications in diagnosis, therapy, and prevention of liver diseases as well as precision medicine in hepatology. (HEPATOLOGY 2017;66:1323-1334.
I
n the 21st century, the view on diseases is rapidly changing. Novel high-throughput technologies and advanced computation with possibilities to sequence and understand the context of each individual genome impact the practice of medicine. Despite this technological revolution, a number of complex disorders, such as the nonalcoholic fatty liver (NAFL) pathologies, still suffer from limitations with regard to early prediction or treatment. We are impeded by the complexity of interactions among numerous components. The liver is the major factory of the human body. This organ guides endobiotic and xenobiotic metabolism and impacts each organ of the body. Liver pathologies result from a complex network of perturbations that occur across different scales of time and space and can be caused by any disturbance of the liver function, including metabolic insults, infections, or drugs. The disease development and progression thus shows nonlinear dynamics that exceed our traditional methods of exploration. In such cases, systems approaches with mathematical modeling and computational tools can greatly assist in understanding the limits of physiological responses and the borders between healthy and disease states.
Despite versatile functionality, the architecture of the liver is remarkably consistent with numerous subsystems, such as hepatocytes (and nonparenchymal cells) as well as four types of vessels, edged with bile ducts, portal vein, and hepatic artery (liver lobules). Computational modeling of lobules is used for studying hepatotoxicity (1) as well as hepatic responses to, and disposition of, xenobiotics. (2, 3) Due to this structural consistency, modeling of liver architecture is quite straightforward, (4, 5) which we cannot say for modeling of liver dynamics. The liver structure is uniform, whereas its metabolic behavior is not. This is represented by a variety of hepatic metabolic abnormalities, such as nonalcoholic fatty liver disease (NAFLD) with risk of progression to nonalcoholic steatohepatitis (NASH), liver cirrhosis, and hepatocellular carcinoma (HCC). (5) Only a few systems approaches are available for studying the pathogenesis of NAFLD (6) (examples of models with this focus are presented in earlier work (7, 8) ), where the liver communicates through the blood with other organs in response to intra-and extracellular signals. Oxygenation and cell polarity additionally contribute to the complexity of the dynamic approaches. (9) Hepatocytes represent 60% of liver cells with around 80% of parenchymal volume and are responsible for the synthesis of 90% of liver proteins. (10) Comprehensive understanding of hepatic metabolism can be acquired only upon understanding correlations between hepatocytes and other liver cell types. It is also important to account for the intertissue metabolite transport and intracellular communication, which is not usual practice in the state-of-the-art modeling approaches. (7) Herein, we review the state-of-the-art computational models that describe liver dynamics from the metabolic, gene regulatory, and signal transduction perspectives. In particular, we focus on large-scale models, which almost completely cover hepatic metabolism and discuss potential clinical applications.
Computational Approaches for Modeling Liver Metabolism
Improvements in analysis of gene expression, proteomics, and metabolomics produce increasing amounts of quantitative data. These data can be applied for derivation of computational models and to clarify hidden principles by classification of interactions among components. The dynamic computational models can be, in contrast to static models, used to perform in silico simulations and analyses. (11) Simulations are an enormously rich source of new data that can be difficult (or even impossible) to obtain experimentally and can be used to form novel testable hypotheses.
Dynamic models are further classified as qualitative and quantitative. (12) Qualitative models give only descriptive information, such as the presence or absence of an observed component. Quantitative models can refer to actual quantities of observed components in the system of interest, such as the subcellular compartment, cell, or tissue organ, giving precise answers and more information about the system's properties. Building quantitative models of complex systems is a difficult task because a large quantity of kinetic data are needed. A compromise between the two approaches is represented by semiquantitative models. (13) These type of models require only partial data and yield quantitative results that do not necessarily correspond to absolute quantities in the system. Semiquantitive models are easier to establish than quantitative models, whereas are more accurate than qualitative models.
GENOME-SCALE MODELING
Genome-based models (GEM) are derived from the genome-scale metabolic network (GSMN) reconstruction describing metabolism-related reactions within the whole organism. GSMN is primarily reconstructed from the genome annotations as well as from literature data (see Fig. 1 ). GSMN involves steps such as functional annotation of the genome, identification of the metabolism-associated reactions, and determination of their stoichiometry, directionality, and compartmentalization, determination of the biomass composition, estimation of energy requirements, and definition of additional model constraints. This information can be integrated into a stoichiometric representation of metabolism that can be used for detailed analysis of metabolic potentials using constraint-based modeling approaches. (14) Benefits of GSMN modeling lie in the simplicity of model reconstruction, where the accurate values of kinetic parameters describing reaction rates are not required. (15) The PubMed database contains an increasing number of articles focused on the GSMN modeling from 2009 and thereafter, reflecting that GSMN presents the current state of the art. (16, 17) GSMN reconstruction is theoretically possible for all biological networks because large data sets generated from high-throughput techniques in transcriptomics, proteomics, and metabolomics can be applied for reconstruction together with general biochemical data. (18) Cell-type-specific GSMNs have been reconstructed using automated and semiautomated processes (18) from generic GSMNs with dedicated algorithms (see Table 1 ) that depend on specific omics data. Schlomi et al. (19) generated 10 human cell-type-specific models by integrating transcriptome data into the GSMN with improved flux prediction. Regulatory information was included in the expression data to give additional constraints on metabolic fluxes. (20) Similar algorithms were used in GSMN reconstructions for cardiomyocytes, (21) alveolar macrophages, (22) brain, (23) kidney, (24) hepatocytes, (8, 25, 26) adipocyte, (27) and a hepatocytemyocyte-adipocyte-connected model. (28) Eventual gaps that arise during the GSNM reconstruction may be filled manually with the literature data or by using gap-filling methods (29) and algorithms, which are already built in different dedicated computational toolboxes, such as Reconstruction, Analysis, and Visualization of mEtabolic Networks (RAVEN) (30) and COnstrained-Based Reconstruction and Analysis (COBRA). (31) Gap-filling methods identify gaps by searching for blocked metabolites and then minimize their numbers with minimal modifications (e.g., changing reaction reversibility and adding "gap-filling" reactions). (32) Databases like BRaunschweig ENzyme DAtabase (BRENDA), (33) COMPARTMENTS, (34) and The Human Protein Atlas (35) provide subcellular localization data obtained from the literature, thus manual curation is absolutely necessary. A helpful manual for all stages of the GSMN reconstruction process is provided by Thiele et al. (36) These stages are summarized in Fig. 1 . Transformation of GSMNs into dynamic mathematical models can be performed with constraintbased modeling, (18) which is based on the flux balance analysis (FBA) method and its variations. Model simulations can be used to predict the flow of metabolites through the metabolic network under steady-state presumption. (37) Solutions describing the metabolites flow can be further constrained with objective functions, such as maximal growth. FBA approaches are unable to directly address the regulatory and signaling reactions that may significantly affect the metabolic responses. (32, 37) These can, however, present additional constraints to the FBA with the combinations of different simulation strategies. (32) OBJECT-ORIENTED MODELING Object-oriented modeling (OOM) focuses on the identification of biological objects each described with its functions and attributes to accomplish a specific behavior. Applying this concept to biological entities and their correlations has recently proven to be successful also in systems biology. For example, large macromolecules can be regarded as objects and signaling pathways as information passing between objects through their connections. A visual representation can help to organize and manage complex networks without losing the system's integrity. (38) (74) (integrated Metabolic Analysis Tool) -Predicting reaction fluxes based on microarray and proteomic data based on the method previously described by Shlomi et al. (19) -Available online and as part of the COBRA and TIGER toolbox. GIMME (75) (Gene Inactivity Moderated by Metabolism and Expression)
-Uses microarray data and some presupposed metabolic objectives to produce the context-specific reconstruction that is most consistent with the available data. -Require manual curation.
-Available as part of the COBRA and TIGER toolbox.
GIMMEp (76) (Gene Inactivity Moderated by Metabolism and Expression by Proteome) -Improved original GIMME method by integrating proteomic data for additional identification of metabolic functions. -Require manual curation.
E-Flux (77) -Based on FBA and extended with modeling maximum flux constraints as a function of measured gene expression. It applies a model of the underlying metabolic network for prediction of changes in metabolic flux capacity.
MBA (26) (Model-building Algorithm)
-Collected tissue-specific data out of a generic species model, based on existing literature and molecular data typical for the tissue's metabolism. It is structured according to the accuracy level of the input data by the division of the tissue-specific information into manually curated and omics data, which are regarded with different confidence.
IOMA (78) (Integrative Omics-metabolic Analysis)
-A quadratic programming problem that seeks a steady-state flux distribution in which flux through reactions with measured proteomic and metabolomics data, is as consistent as possible with kinetically derived flux estimations for predicting metabolic flux distributions. -Available online. tFBA (79) (Time-linked Flux Balance Analysis) -Algorithm with regulatory up/down (not regulatory on/off which is usually used in Boolean network) constraints based on gene expression data in FBA optimization.
MADE (80) (Metabolic Adjustment by Differential Expression)
-Uses an optimization-based approach to create a sequence of binary expression states that reflect the most statistically significant changes in the series of gene expression measurements; it doesn't require usage of arbitrary expression thresholds for each gene. -Available online and as part of the COBRA and TIGER toolbox.
INIT (43) (Integrative Network Inference for Tissues) -Uses cell-type-specific information from Human Proteome Atlas as the main source of data and allows simulation-ready models based on omics data coupled with defined metabolic tasks.
tINIT (47) ( Task-driven Integrative Network  Inference for Tissues) -Improvements over the original INIT algorithm: (1) constrains the solution that reversible reactions can't have flux in both directions simultaneously and (2) users choice in case of allowing net production of all metabolites. -Available as part of the RAVEN toolbox. mCADRE (49) (metabolic Context-specificity Assessed by Deterministic Reaction Evaluation) -Produces models with similar or better functionality like INIT/tINIT and achieves computational speed-up. -Includes a metabolic function test (checkModelFunction) in the model building process. FASTCORE (81) -Allows the performance of multiple runs in order to optimize extra parameters or test different core sets obtained from the primary data set.
-Available as part of the COBRA toolbox. PRIME (44) (Personalized Reconstruction of Metabolic models) -For reconstruction of phenotype-based, cell-specific metabolic models based on both molecular and phenotypic data. -Prediction of metabolic phenotypes in an individual manner, including growth rates and drug response.
Numerous approaches that use dedicated algorithms described in the table have been applied to automated GSMN reconstruction on the basis of high-throughput experimental data.
Modelica is among the most popular programing languages for OOM (https://www.modelica.org). Users are free to create their own model libraries or just modify the existing libraries according to their own needs. A Modelica library BioChem is designed for modeling, simulating, and visualization of metabolic pathways. (39) The components of this model library describe basic substances and general reactions that are common in metabolic pathways and can be easily adapted.
Even though Modelica is currently used mostly in industrial applications, large-scale systems biology models such as HumMod (40) and computational models of the cardiovascular, respiratory and thermoregulatory systems and their corresponding control mechanisms (41) have already been established. HumMod contains over 4,000 variables describing cardiovascular and nutrition system, metabolism, hormone regulation, status of virtual patient, and set-up components. Users can simulate a wide range of pathological stages, including the effects of the applied therapy. Both models are based on experimental and literature knowledge, were built manually, and are able to reproduce the behavior of physiological and pathophysiological states.
Computational Models of Liver Metabolism
In this section, we review state-of-the-art large-scale computational models focused on the human liver metabolism: the GMSN (see section "Genome Scale Metabolic Models") and object-oriented (see section "Object-Oriented Modeling") models, summarized in Table 2 .
GENOME SCALE METABOLIC MODELS HepatoNet1
HepatoNet1 (25) is an adaptation of the first global human metabolic network, Recon1, (42) to represent the hepatocyte. HepatoNet1 contains most of hepatocyte organelles (compartments) and also bile canaliculus and sinusoidal space with over 800 metabolites ( Table 2 ). The metabolic entities are connected with either physical reactions and transport processes (enzyme-catalyzed reactions, spontaneous reactions, diffusion, and transport reactions) or abstract reactions for which exact dynamics are either unknown or may be simplified in the model. Reactions are described on the basis of experimental evidence from human hepatocytes, on the basis of liver in general, or by orthologue evidence from other mammalian species.
The functionality of HepatoNet1 was tested with in silico replication of bile acid synthesis during starvation and oxygen demand for ammonia detoxification. Robustness was analysed by performing 123 computational knockdown studies. (25) The clinical utility of this hepatocyte model is in revealing dependencies between the available level of oxygen and variations in the substrate demand for effective ammonia detoxification, which is of crucial importance in preventing the toxic effect of ammonia in hepatic encephalopathy (HE). iHepatocyte2322 (8) is based on a combination of clinical, biochemical, and genetic studies for identification of biomarkers and therapeutic targets in NAFLD. This model includes over 5,500 metabolites (Table 2) in different compartments. It differs from previous models regarding the lipid metabolism, which includes the uptake and secretion of very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) lipoproteins, and the formation and/or degradation of lipid droplets. Integration of lipid metabolism allows a better understanding of metabolic disease progression.
iHepatocyte2322 was reconstructed with the Integrative Network Inference for Tissue (INIT) algorithm, combining large-scale proteomics data and the Human Metabolic Reaction (HMR; GSMN model for the generic human cell), (43) which was expanded with lipid metabolism. At the same time, the developers merged previously published hepatocyte models to cover metabolic functions. Model validation was performed on 256 hepatocyte functions with the checkTasks method available from the RAVEN Toolbox. (30) iHepatocyte2322 provides novel further insight into NAFLD. After simulation of NAFLD progression to NASH, serine deficiency was observed in NASH patients. (8) The conclusion obtained from computational results was that increasing serine levels in hepatocytes through the uptake of serine as a dietary supplement could prevent NASH progression. Activation of PSPH (phosphoserine phosphatase) and SHMT1 (serine hydroxymethyltransferases 1) or inhibition of BCAT1 (branched chain amino-acid transaminase 1) is involved in regulation of serine levels in hepatocytes, and the involved proteins were identified as potential therapeutic targets for the treatment of NASH.
Hepatocellular carcinoma GSMN
Different cancer GSMNs have also been reconstructed to date to provide novel insights in the benefit cancer cells receive from tumor-specific metabolic modifications GSMN. (18, (43) (44) (45) (46) The Hepatocellular carcinoma GSMN (47) model presents the adaptation of generic cancer models, which were applied to personalized GSMN for HCC patients. This model contains close to 4,500 metabolites in different compartments (Table 2 ). Proteomic profiling (using immunohistochemistry data) of 27 HCC patients provided better discrimination of tumor appearances and a tool for searching potential anticancer drugs. A personalized GSMN model based on proteomic data and HMR 2.0 (8) was reconstructed for 6 HCC patients using the tINIT algorithm. Comparison of simulation results for compounds that could inhibit tumor growth identified 101 antimetabolites with tumor suppression effect in HCC patients. This comparison pinpointed to icarnitine, suppressing HCC growth by inhibiting boxidation. The prediction was additionally validated by literature evidence and in vitro experiments. In a similar way, the iHCC2578 (48) model was constructed to study acetate utilization and to improve the knowledge about HCC. Deregulation of fatty acid oxidation was identified as the ultimate metabolic process needed for cell proliferation in HCC.
liverCADRE
The metabolic Context-specificity Assessed by Deterministic Reaction Evaluation (mCADRE) (49) method (Table 1 ) was used to reconstruct a cell-typespecific model based on gene expression data and metabolic network topology. Reconstruction was performed with transcriptomic data of 23 healthy liver individuals. Details of liverCADRE are shown in Table  2 . The same data were used to compare the mCADRE method to the Model-building Algorithm (MBA ;  Table 1 ), where mCADRE demonstrated significantly better results. (26) A Tissue-Specific Encyclopedia of Metabolism was built with the mCADRE method, which included 30 models covering distinct brain structures-this may again be important in the context of the liver-to-brain communication.
OBJECT-ORIENTED MODELING SteatoNet
SteatoNet (7) is a large-scale model based on the OOM describing the interactions between the liver and peripheral tissues (Fig. 2) . This model provides a dynamic, multicompartmental, in silico abstraction of previously identified and candidate metabolic pathways involved in NAFLD pathogenesis. SteatoNet includes feedback regulation at the level of protein expression and activation and at the transcriptional level, which have significant roles in liver functionality. This model is based on a steady-state analysis of ordinary differential equations (ODEs) that do not require kinetic parameters and can uniquely identify a solution by just defining the reversibility of reactions, distribution of fluxes at pathway branch-points, and substrate influx into the network.
Although SteatoNet is smaller compared to abovedescribed GSMNs, its benefit is inclusion of extrahepatic tissues connected to hepatocyte through the blood (Table 2) , as well as inclusion of transcription factors that are crucial regulators of metabolic processes whose disrupted signaling can trigger NAFLD. SteatoNet uses a unique systems biology library, SysBio (http://lrss.fri.uni-lj.si/bio/sysbio/). The properties and dynamics of each object in the library are determined by ODEs that have been assigned to the biological function of each object. The most important reaction object corresponds to enzyme-catalyzed biochemical reaction based on Michaelis-Menten enzyme kinetics.
SteatoNet is able to predict that NAFLD does not appear only attributed to irregular metabolism of hepatocytes. Interactions between adipose tissue and liver were identified as critical for the pathogenesis of NAFL. SteatoNet not only confirmed the hepatic triglyceride sensitivity to previously identified deregulations in NAFL, but identified also novel candidate mechanisms, such as cholesterol transport, ketone body metabolism, and regulatory functions of farnesoid X receptor, liver X receptor, and sterol regulatory element-binding protein 2. The personalization of SteatoNet can be additionally aimed at prediction of the network effects of other liver-related diseases in individuals. Recent (unpublished) simulations reveal that it can be applied to address the sexual dimorphism in liver pathologies.
Clinical Applications
Computational models provide predictions that can be used for diagnostic purposes or identification of drug targets for personalized and systems-based care in patients with liver diseases, when data are difficult to obtain experimentally. These data ultimately need to be validated for their clinical impact on important patient-centric outcomes, such as overall survival or quality of life. To date, only a few systems medicine approaches in hepatology have been translated to clinical application. Small progress, such as the identification of the interleukin 28B polymorphisms predicting response to therapy of hepatitis C virus (HCV) infection, (50, 51) was quickly outdated with the introduction of the new interferon-free treatment regimens. Thiopurine methyltransferase testing to predict the risk of toxicity from azathioprine in treatment of autoimmune hepatitis has not yet replaced the need to clinically and biochemically monitor these patients. Despite large efforts to develop personalized systemsbased care for patients with HCC, individualized options are not available yet. (52) The computational models presented in this review, especially large-scale models with a broad coverage of the hepatic metabolism and including multiple tissues and their interactions, such as HepatoNet1 and SteatoNet, can be used to advance the translation of systems biology approaches to clinical applications.
RESEARCH ON CANCER AS TRAILBLAZER
Research in personalized care in oncology has yielded powerful examples of the successful application of systems biology. Based on identification of molecular profiles in large genetic databases, such as the International Cancer Genome Consortium, (53) individualized and significant therapeutic improvements were introduced for gastrointestinal stromal tumors, (54) non-small-cell lung cancer, (55) melanoma, (56) HER2-positive breast cancer, (57) ovarian, (58, 59) and colorectal cancer. (60) For example, the HCC GSMNs based on proteomic profiling (48, 61) resulted in improved HCC stratification and suggested novel molecular targets (e.g., carnitine palmitoyltransferases and acetyl-CoA synthetases) for personalized treatment strategies of HCC.
Using similar approaches, the diagnosis, treatment, and prevention of several other chronic liver diseases may benefit from further defining their specific genetic and metabolic profiles. Examples include the identification of parameters predicting outcome for improved allocation of liver transplants and models for timing of liver transplantation in acute liver failure, refractory primary biliary cholangitis, as well as primary and secondary biliary cholangitis, cholangiocarcinoma, and NAFLD with its potential transformation to NASH, cirrhosis, and HCC.
CURRENT CLINICALLY APPLICABLE COMPUTATION MODELS
Several clinically applicable mathematical therapyguiding or biomarker-detecting models for liver diseases were developed as smaller-scale and/or non-objectoriented or non-GSMN models, as summarized in Table 3 . Complete coverage of hepatic metabolism is not provided in these models. One of the first examples were models predicting HCV viral load during treatment to assess the dynamics of HCV replication, (62) which were later expanded and applied in clinics. (63, 64) Current applications focus on metabolic consequences of acute and chronic liver failure, such as dysregulation of ammonia detoxification. Schliess et al. (65) investigated using an integrated spatial-temporal model how liver injury affects ammonia detoxification, which represents a critical step in the development of HE. The metabolic model was based on mass balancing and mouse liver perfusion data and combined with a spatialtemporal model simulating liver tissue damage and regeneration after CCl 4 intoxication in mice, but was not consistent with some of the experimental findings. Therefore, by adding glutamate dehydrogenase (GDH) to the model, an improved version was developed. (66) GDH and its cofactors could reverse the condition and are candidates for future treatment of hepatic encephalopathy. Noiret et al. (67) evaluated the extent of portosystemic shunting in cirrhosis and the association with hyperammonaemia. The model could predict that portosystemic shunting independent of the liver function was sufficient to cause hyperammonia. (68) Smaller-scale mathematical models identifying potential biomarkers or therapeutically targetable mechanisms.
Acetaminophen-induced liver jury is a prominent cause of acute liver failure. Remien et al. (68) developed the Model for Acetaminophen-induced Liver Damage (MALD), based on clinical data from 53 patients. MALD could accurately predict outcome and potential necessity for liver transplantation after ingestion of acetaminophen overdose. Such human studies are to be complemented by preclinical models of acetaminophen-induced acute and acute-on-chronic liver failure. Here, modeling could help to improve liver function diagnostics. For this, the metabolic core models such as HepatoNet1 are expanded to include the elimination of galactose, metabolism of caffeine, or detoxification of methacetin, all of which represent test substances used in quantitative liver function tests in the clinic. (69) 
FUTURE CLINICAL TRIALS
Even though some clinically applicable results from mathematical models are available, the model predictions generated in systems medicine approaches need to be further validated in alternative interventions in vitro and in vivo. A major hurdle in translating these models, before they can be implemented into clinical decision making and guidelines for clinicians, is the precise validation of the model predictions in adequately designed clinical trials, which has yet to be achieved. A model integrating liver metabolism into a physiologically based pharmacokinetic model could substantially improve the prediction of human pharmacokinetics based on animal data, (70) which is an important prerequisite for translation to clinical studies in humans.
Currently, clinical trials are predominantly not controlled for individual (epi)genetic predisposition or signal transduction or metabolic profiles and are thus not accounting for nonrandom variation. With large numbers of patients being required, the challenge to recruit sufficient patient numbers to validate individual variants in clinical trials seems huge. These challenges have led to new designs for clinical trials, with oncology at the forefront. Strategies to increase power and robustness of the models by including homogenous patient samples, may involve the inclusion of as few individuals as possible who are unlikely to respond to therapy; other options include a selective analysis of biomarker-positive patients (possibly with discovery of biomarkers during the clinical trial and/or using a combination of biomarkers) or conducting the trial in a (genetically) stratified risk population.
A recent design developed in trials in oncology is the umbrella trial, which investigates a single cancer type selected according to the biomarkers relevant to the candidate drugs. In contrast, basket trials are conducted for different tumor types stratified for their molecular profiles. (71) Efficient allocation of scant numbers of patients can be achieved by flexible study master protocols, using multiplex diagnostic assays before inclusion, such as a tent protocol. (71) These novel designs have to be adapted for the specific needs in systems hepatology. Different from malignant diseases, it needs to be investigated which alterations in the involved tissue (liver) are of relevance for patientcentric outcomes. This creates more complexity for the acquisition and interpretation of data from patients with liver diseases. In the future, broad molecular profiling of liver diseases derived from predictions of computational models, and validation of the results in welldesigned clinical trials, could improve the currently unsatisfying treatment options for many liver diseases with respect to individualized care.
Conclusions
Even though clinical applicable models in hepatology are currently limited in number and represent predominantly smaller-sized models, which are not yet validated in clinical trials in humans, a majority of the presented computational models have biological/clinical applications and could be used as diagnostic, target drug identification or predictive and analytical tools for personalized treatment of patients with liver diseases. The future of metabolic modeling holds exciting opportunities to model multiple organs. One of the ambitious aims is to have 90% of the human body computationally designed by 2038. (72, 73) The efforts of the systems biology and specifically the systems medicine community are currently directed toward this goal. Virtual human body design is in progress, but advancing slowly because of problems arising from the necessity to capture all information from spatial, chronological, metabolic, and regulatory levels of the human.
